伴TP53异常MDS/AML患者接受异基因造血干细胞移植的生存疗效
回顾性分析42例伴TP53基因异常的MDS/AML患者接受allo-HSCT的结局,中位随访34.0个月,移植后3年OS率66.3%、EFS率61.0%;TP53缺失组、单基因突变组、多打击组3年OS与EFS无统计学显著差异;移植前原始细胞阳性为OS独立危险因素。
要点
- 伴TP53异常MDS/AML患者接受allo-HSCT后3年OS率66.3%、EFS率61.0%。
- TP53缺失组、单基因突变组、多打击组3年OS与EFS无统计学显著差异。
- 移植前原始细胞阳性是OS独立危险因素(HR=33.40)。
核心结论
- allo-HSCT可改善伴TP53基因异常MDS/AML患者的不良预后,但伴有复杂核型的TP53异常患者预后较差。
- 移植前末次流式细胞术检测骨髓原始细胞对预后评估具有一定的指导意义。
研究设计与样本
- 回顾性分析2014年8月1日至2021年7月31日于中国医学科学院血液病医院接受allo-HSCT的42例伴TP53基因异常MDS/AML患者。
- 42例患者分为TP53缺失组(A组)、TP53单基因突变组(B组)和TP53多打击组(C组)。
主要发现
- 全部42例中MDS与AML各21例,中位移植年龄41.5(18~63)岁,中位随访34.0(7.5~75.0)个月。
- 移植后3年OS率为66.3%(95%CI 53.4%~82.4%),3年EFS率为61.0%(95%CI 47.7%~78.0%)。
- TP53缺失组、单基因突变组、多打击组3年OS率分别为82.5%(95%CI 63.1%~100.0%)、60.6%(95%CI 43.5%~84.4%)、57.1%(95%CI 30.1%~100.0%),χ²=3.100,P=0.200。
- 三组3年EFS率分别为80.8%(95%CI 60.0%~100.0%)、55.0%(95%CI 37.8%~80.3%)、50.0%(95%CI 25.0%~100.0%),χ²=0.900,P=0.600。
- 多因素分析显示移植前原始细胞阳性是OS的独立危险因素(P=0.037,HR=33.40,95%CI 1.24~901.17)。
关键数值与推荐
- 单因素分析发现年龄、复杂核型、共突变、移植前原始细胞阳性、移植后原始细胞阳性为OS、EFS的共同预后不良因素。
- 单因素分析显示共突变基因数、移植前治疗、疾病类型不影响预后。
- 多因素分析显示移植前原始细胞阳性是OS的独立危险因素(P=0.037,HR=33.40,95%CI 1.24~901.17)。
临床怎么用
- 作者认为allo-HSCT可改善伴TP53基因异常MDS/AML患者的不良预后。
- 作者认为伴有复杂核型的TP53异常患者预后较差。
- 作者认为移植前末次流式细胞术检测骨髓原始细胞对预后评估具有一定的指导意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: TP53-abnormal MDS/acute myeloid leukemia (AML) patients' allogeneic hematopoietic stem cell transplantation (allo-HSCT) treatment's effectiveness and influencing factors should be studied. Methods: 42 patients with TP53 gene status change MDS/AML who underwent allo-HSCT from 2014.8.1 to 2021.7.31 at the Hematology Hospital of the Chinese Academy of Medical Sciences were the subject of a retrospective analysis. The 42 patients were divided into three groups: the TP53 deletion group (group A) , TP53 mono-alle mutation group (group B) , and TP53 multi-hit group (group C) . The differences in clinical features and prognostic factors after transplantation were analyzed. Results: There were 42 MDS/AML patients, including 21 patients with MDS, and 21 patients with AML. The median follow-up period was 34.0 (7.5-75.0) months and the median patient age at the time of transplantation was 41.5 (18-63) years old. The total OS was 66.3% (95% CI 53.4%-82.4%) in 3 years after transplantation, and EFS was 61.0% (95% CI 47.7%-78.0%) in 3 years. For 3 years after receiving hematopoietic stem cell transplantation, there were no statistically significant differences in 3-year OS and EFS in groups A, B, and C (P≥0.05) . The 3 years OS was 82.5% (95% CI 63.1%-100.0%) in group A, 60.6% (95% CI 43.5%-84.4%) in group B, and 57.1% (95% CI 30.1%-100.0%) in group C. Univariate analysis revealed that the number of co-mutant genes, pre-HSCT treatment, and disease type did not affect prognosis, while age, karyotype, co-mutation, positive blast cell before transplantation, and positive blast cell after transplantation were common prognostic factors for OS and EFS (P<0.1) . MRD levels before transplantation were found to be independent risk factors for OS (P=0.037, HR=33.40, 95% CI 1.24-901.17) in a multivariate analysis. Conclusion: Patients with MDS/AML who have TP53 mutations can benefit from allo-HSCT, but patients with complex karyotypes have a worse prognosis. Meanwhile, the final flow cytometry (FCM) monitoring blast cell test before HSCT has a certain guiding significance for prognostic assessment. 目的: 探讨异基因造血干细胞移植(allo-HSCT)治疗伴TP53基因异常骨髓增生异常综合征(MDS)/急性髓系白血病(AML)患者的疗效及影响因素。 方法: 纳入2014年8月1日至2021年7月31日期间于中国医学科学院血液病医院接受allo-HSCT的42例伴TP53基因异常的MDS/AML患者,根据TP53异常情况分为TP53缺失组、TP53单基因突变组和TP53多打击组,回顾性分析各组患者的临床特征、移植疗效及其预后影响因素。 结果: 全部42例患者中包括MDS、AML患者各21例,中位移植年龄为41.5(18~63)岁,中位随访时间为34.0(7.5~75.0)个月。移植后3年总生存(OS)率为66.3%(95%CI 53.4%~82.4%),3年无事件生存(EFS)率为61.0%(95%CI 47.7%~78.0%)。TP53缺失组、TP53单基因突变组、TP53多打击组移植后3年OS率分别为82.5%(95%CI 63.1%~100.0%)、60.6%(95%CI 43.5%~84.4%)、57.1%(95%CI 30.1%~100.0%)(χ(2)=3.100,P=0.200),EFS率分别为80.8%(95%CI 60.0%~100.0%)、55.0%(95%CI 37.8%~80.3%)、50.0%(95%CI 25.0%~100.0%)(χ(2)=0.900,P=0.600)。单因素分析发现,年龄、复杂核型、共突变、移植前原始细胞阳性、移植后原始细胞阳性为OS、EFS的共同预后不良因素。多因素分析显示移植前原始细胞阳性是OS的独立危险因素(P=0.037,HR=33.40,95%CI 1.24~901.17)。 结论: allo-HSCT可改善伴TP53基因异常MDS/AML患者的不良预后,但伴有复杂核型的TP53异常患者预后较差。移植前末次流式细胞术检测骨髓原始细胞对预后评估具有一定的指导意义。.
引用
- Feng D, Wang MY, Liu J, et al. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37356984. doi:10.3760/cma.j.issn.0253-2727.2023.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。